Related Experiment Video

Updated: Jul 20, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

The role of vasopressin in congestive heart failure

Steven R Goldsmith1

  • 1Division of Cardiology, Hennepin County Medical Center, Minneapolis, MN 55415, USA. srg_hcmc@yahoo.com

Cleveland Clinic Journal of Medicine
|September 15, 2006
PubMed

Insights

Neurohormonal abnormalities worsen congestive heart failure (CHF). Blocking the arginine vasopressin (AVP) system with antagonists offers a promising new treatment strategy to improve patient outcomes in CHF.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Neurohormonal system activation is central to congestive heart failure (CHF) pathophysiology.
  • Current treatments for CHF focus on inhibiting the renin-angiotensin-aldosterone and sympathetic nervous systems.
  • Excessive arginine vasopressin (AVP) secretion can negatively impact physiological processes in CHF patients.

Purpose of the Study:

  • To explore the potential of inhibiting arginine vasopressin (AVP) as a therapeutic strategy for congestive heart failure (CHF).

Main Methods:

  • Review of existing literature on neurohormonal systems in CHF.
  • Analysis of the role of arginine vasopressin (AVP) in CHF pathophysiology.
  • Evaluation of vasopressin receptor antagonist therapy as a potential treatment.

Main Results:

  • Therapeutic interruption of activated neurohormonal systems improves CHF prognosis.
  • Excessive AVP secretion has detrimental physiological effects in CHF.
  • Vasopressin receptor antagonist therapy shows potential for beneficial effects in CHF.

Conclusions:

  • Inhibition of arginine vasopressin (AVP) via receptor antagonists represents a promising therapeutic avenue for managing congestive heart failure (CHF).
  • Targeting the AVP system could offer a novel approach to improve clinical outcomes in CHF patients.

More Related Videos

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.